Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Weekly channel feed
JPM's M&A Monday frenzy; Ozempic selected for IRA negotiations; Pfizer says it's back on track; and more
5 months ago
DNA edit leads to apparent cure in infant; CDER director to step down; More biotechs emerge with assets from China; and more
5 months ago
Neumora fails Ph3 depression study; Our review of 2024 megarounds; Pfizer cuts Sangamo pact; and more
6 months ago
2024's biopharma winners and losers; CagriSema falls short; Merck swings China GLP-1 deal; and more
6 months ago
The Endpoints 100 is back; Inside Isomorphic Labs; FDA adcomm discusses severe RSV cases; and more
6 months ago
Lilly beats Novo in weight loss; Apogee plots Dupixent challenge; Biosecure compromise coming?; and more
7 months ago
Trump announces picks for FDA, CDC; Novartis seeks bolt-on deals, raises guidance; RFK Jr., Elon Musk may find banning ads difficult; and more
7 months ago
Trump picks RFK Jr. for HHS; AbbVie's psych implosion; Merck tries staving off Summit; and more
7 months ago
How Trump, RFK Jr. could influence biopharma; Viking presents weight loss data; Are MASH drugs getting boxed out by GLP-1s?; and more
8 months ago
How RFK Jr. might influence the FDA; Pharma's Q3 highlights; AbbVie's latest neuro buyout; and more
8 months ago
Latest salvo in Pfizer activist fight; John Carroll's Q3 biotech roundup; Intellia unveils CRISPR results; and more
8 months ago
A Q&A with a Nobel Prize winner; Pfizer meets with Starboard; J&J reports Q3 earnings; and more
8 months ago
Pfizer's situation with Starboard; Meet Endpoints' 2024 Women in Biopharma; Nobel Prizes highlight AI era
9 months ago
WuXi companies consider sale of units impacted by Biosecure; J&J, Bayer trim staff; Ron Renaud’s latest biotech; and more
9 months ago
Meet this year’s Endpoints 11; J&J winds down cardiovascular and metabolic unit; BMS wins schizophrenia approval; and more
9 months ago
John Carroll on his cancer diagnosis; #ESMO's biggest surprise; Lykos' bad trip; Rate cuts, and more
9 months ago
House passes Biosecure Act; Moderna outlines more cost cuts; What's happening at #ESMO24; and more
9 months ago
Notable shakeups this week; Recursion's mixed data; Eli Lilly's $1B bet; and more
10 months ago
FDA authorizes Novavax Covid booster; Recursion nears key data readouts; What’s next for CD47?; and more
10 months ago
Tome plans layoffs amid struggle; FDA turns away Regeneron; Next-gen obesity startup launches; James Sabry joins BioMarin; and more
10 months ago
Unpacking IRA price negotiations results; Lykos’ tough week; Genentech rethinks cancer immunology; and more
10 months ago
Latest on MDMA rejection; Novo vs. Lilly earnings; Recursion, Exscientia to merge; Q&A with Genentech CEO; and more
11 months ago
Eisai’s new Leqembi data; Jim Wilson’s next move; Roivant dealmaker’s payday; What’s next for MDMA?; and more
11 months ago
Mapping GLP-1 game plans; Q2 earnings highlights; J&J vets regroup at startup; and more
11 months ago
First page
Previous page
1
2
3
4
5
Next page
Last page
